Metabolomic Biomarkers for Monitoring Tuberculosis Treatment Response: A Comprehensive Literature Review

Résumé fourni par la source

Background: Tuberculosis (TB) remains a major global cause of morbidity and mortality. Current tools for monitoring treatment response rely on sputum-based microscopy and culture, which may be insensitive, time-consuming, and impractical in extrapulmonary or pediatric TB and in individuals unable to produce sputum. Metabolomics has emerged as a promising approach to identify host-derived biomarkers reflecting treatment-associated immunometabolic changes, but evidence remains heterogeneous and incompletely synthesized. Methods: We conducted a comprehensive literature review of metabolomic biomarkers associated with TB treatment response. PubMed, Scopus, and Web of Science were searched for human studies evaluating targeted or untargeted metabolomics (NMR, LC-MS, GC-MS, CE-MS) in relation to treatment response or outcomes. Two reviewers independently screened studies, extracted data, and assessed risk of bias using QUIPS and PROBAST. Findings were synthesized using a structured framework across treatment stages and outcomes. Results: Of 218 records identified, 139 titles/abstracts were screened and 42 full texts assessed; 15 studies met inclusion criteria. Recurrent signals involved amino acid metabolism, particularly the tryptophan–kynurenine pathway, and vitamin/cofactor metabolites (pyridoxate, nicotinamide, trigonelline). Plasma studies frequently reported lipid remodeling and bile acid perturbations, while urine studies highlighted polyamine metabolism (e.g., N¹,N¹²-diacetylspermine) and fatty acid β-oxidation markers. Common limitations included inadequate adjustment for confounders and, in prediction models, small sample sizes and limited external validation. Conclusions: Metabolomic reveals reproducible but heterogeneous immunometabolic changes during TB therapy. Key pathways include tryptophan-kynurenine metabolism, vitamin/cofactor metabolism, lipid remodeling, and urine polyamine pathways. Standardization and prospective multicenter validation are needed for clinical translation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.